ADAR1 polymorphisms are related to severity of liver fibrosis in HIV/HCV-coinfected patients.

ABSTRACT: The adenosine deaminase acting on RNA (ADAR1) gene is an interferon-stimulated gene involved in liver injury protection. Our aim was to analyze the association of polymorphisms within this gene with the severity of liver disease in European HIV/HCV-coinfected patients. We performed a cross-sectional study in 220 patients that underwent a liver biopsy. Five SNPs in the ADAR1 gene (rs1127326, rs1127317, rs1127314, rs1127313, rs2229857) were genotyped by GoldenGate assay. The outcome variables were fibrosis stage and necroinflammatory activity grade by METAVIR-score, aspartate aminotransferase to platelet ratio index (APRI), FIB-4 index, and fibrosis progression rate (FPR). In multivariate analysis, fibrosis progression rate (FPR) (aAMRs?=?0.97) decreased in a dose-dependent manner with the presence of rs2229857_T, rs1127313_G, rs1127314_G and rs1127317_G; while rs1127326_T allele had only significant associations with FIB-4 (aAMRs???0.63) and FPR (aAMRs???0.97). Moreover, carriers of rs2229857_T, rs1127314_G, rs1127317_G, and rs1127326_T alleles were protected against advanced fibrosis (F???3) (adjusted ORs (aORs)???0.44), APRI???1.5 (aORs???0.33), and FPR???0.075 (aORs???0.45). rs1127313_G carriers showed lower odds of having F???3 (aORs?=?0.39), FIB4???3.25 (aOR?=?0.22) and FPR???0.075 (aORs?=?0.44). In conclusion, ADAR1 polymorphisms protected against severe liver disease in HIV/HCV-coinfected patients. These results could be used to improve therapeutic decision-making in clinical practice.

SUBMITTER: Medrano LM 

PROVIDER: S-EPMC5635123 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature